Alcobra Ltd. to Present at Investor Conferences in November


TEL AVIV, Israel, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that the Company will provide a corporate overview at two upcoming investor conferences in November.

Credit Suisse Healthcare Conference  
Date: November 12
Time: 7:30AM MST
Location: Arizona Biltmore Hotel, Scottsdale, Arizona
   
Stifel Annual Healthcare Conference  
Date: November 18
Time: 9:10AM Eastern
Location: New York Palace Hotel
Webcast: http://www.alcobra-pharma.com/events.cfm

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and one Phase III study in adults with ADHD. The company is conducting separate Phase IIb trials in pediatric ADHD and Fragile X Syndrome. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.



            

Contact Data